(Reuters) – A COVID-19 vaccine developed by CanSino Biologics Inc and China’s military research unit has shown to be safe and induced immune response in most of the recipients who got one shot, researchers said on Monday.
The CanSino candidate, named Ad5-nCOV, is one of a handful of vaccines that have shown some promise in human testing and gear up for late-stage trials, along with projects involving Moderna, BioNTech and Inovio Pharmaceuticals.
(Reporting by Ankur Banerjee in Bengaluru; Additional reporting by Roxanne Liu; Editing by Miyoung Kim and Shounak Dasgupta)
